Offers Canadians Access to International Innovation and Expertise
through Exclusive Partnership
MARKHAM, ON, Feb. 25, 2014 /CNW/ - MedReleafTM, a Canadian-owned and operated company, has been approved as a licensed
producer under Health Canada's new Marihuana for Medical Purposes Regulations. With this license, MedReleaf is authorized to supply cannabis for
medical purposes to patients across the country.
MedReleaf is the only licensed producer to have an exclusive partnership
with world-renowned medical cannabis innovator, Tikun Olam, the largest
government-approved producer of medical cannabis in Israel. Through
this partnership, patients will have a wide variety of product to
choose from including a dozen of Tikun Olam's proprietary varieties,
all locally grown at MedReleaf's facility in Markham, Ontario. These
proprietary varieties will include Tikun Olam's well-regarded Avidekel™ that is known to contain high levels of CBD and very low levels of THC.
"Our partnership with Tikun Olam provides us with access to exclusive
strains as well as treatment data on more than 7,000 patients," said
Neil Closner, Chief Executive Officer at MedReleaf. "This proprietary
data provides us with a solid understanding of the effectiveness and
efficacy of different medical cannabis varieties on patients."
Together, MedReleaf and Tikun Olam will spearhead studies that examine
the effectiveness of these varieties in the treatment of various
conditions such as nausea, vomiting and weight loss associated with
cancer treatment and chronic pain associated with rheumatoid arthritis,
fibromyalgia, multiple sclerosis, post-operative recovery, HIV/AIDS,
Huntington's and Parkinson's disease, inflammatory bowel disease,
glaucoma and arthritis as well as Tourette's syndrome, epileptic
seizures and other neurological disorders.
"Our focus is on evidence based clinical research to validate the
benefits of medical cannabis on a wide range of conditions and
symptoms, allowing physicians to ultimately provide individualized care
to their patients," said Closner. "We are currently looking to partner
with Canadian physicians on new research initiatives."
MedReleaf's senior leadership team has more than 100 years of combined
experience working with cannabis and treating patients. MedReleaf also
has Patient Care Coordinators available -highly qualified healthcare
professionals who will work with MedReleaf patients to recommend the
strain (or strains) that best meet their therapeutic needs. These
Patient Care Coordinators will also be an essential support resource
for physicians to help them more easily and accurately assist their
"Our goal is for MedReleaf to be recognized as a key player in the
Canadian healthcare industry and to be the most trusted and reliable
producer of medical grade cannabis in the country," added Closner. "We
have industry leading quality control and proven patient protocols
matched with proprietary strains that can't be found anywhere else."
Canadian patients can now sign-up with MedReleaf at www.medreleaf.com
MedReleafTM is a Canadian-owned and operated producer and distributor of medical
grade cannabis. The company operates a 55,000 square foot
state-of-the-art facility in Markham, Ontario. Its leadership team
consists of highly skilled and expert professionals who have more than
100 years of combined experience treating patients and working with
cannabis. They have extensive backgrounds in business, molecular plant
genetics, biotechnology, horticulture, clinical laboratory management
and operations. MedReleaf is dedicated to improving the quality of life
for patients across the country by providing them with a broad range of
the finest quality varieties anywhere in the world. MedReleaf obtained
its license from Health Canada in February 2014.
Image with caption: "MedReleaf Logo (CNW Group/MedReleaf Corp.)". Image available at: http://photos.newswire.ca/images/download/20140225_C7098_PHOTO_EN_37115.jpg
SOURCE: MedReleaf Corp.
For further information:
GoldFenix Communications & Associates
GoldFenix Communications & Associates